Roche's TIGIT fallout causes GSK and iTeos to re-think their own I/O candidate
Both GlaxoSmithKline and iTeos Therapeutics are going to take a hard look at their experimental TIGIT-targeting immunotherapy in the wake of Roche’s fail earlier this week.
EOS-448, an IgG1anti-TIGIT monoclonal antibody designed to engage the Fc gamma receptor (FcγR), is being “reevaluated” by the partners, iTeos revealed in its first quarter financial report Thursday. And there may even be further delays going forward: According to an iTeos company spokesperson in an email to Endpoints News, the three registration-directed trials that were due to potentially kick off around the end of the year now will have to wait until next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.